Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion

Sean P David; David R Strong; Adam M Leventhal; Molly A Lancaster; John E McGeary; Marcus R Munafò; Andrew W Bergen; Gary E Swan; Neal L Benowitz; Rachel F Tyndale; David V Conti; Richard A Brown; Caryn Lerman; Raymond Niaura

doi:10.1111/add.12325

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion

Sean P David, David R Strong, Adam M Leventhal, Molly A Lancaster, John E McGeary, Marcus R Munafò, Andrew W Bergen, Gary E Swan, Neal L Benowitz, Rachel F Tyndale, David V Conti, Richard A Brown, Caryn Lerman, Raymond Niaura

Research output: Contribution to journal › Article (Academic Journal) › peer-review

32 Citations (Scopus)

Abstract

To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies.

Original language	English
Journal	Addiction
DOIs	https://doi.org/10.1111/add.12325
Publication status	Published - 14 Aug 2013

Bibliographical note

Research Groups and Themes

Brain and Behaviour
Tobacco and Alcohol
TARG

Access to Document

10.1111/add.12325

Handle.net

Persistent link

Cite this

David, S. P., Strong, D. R., Leventhal, A. M., Lancaster, M. A., McGeary, J. E., Munafò, M. R., Bergen, A. W., Swan, G. E., Benowitz, N. L., Tyndale, R. F., Conti, D. V., Brown, R. A., Lerman, C., & Niaura, R. (2013). Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction. https://doi.org/10.1111/add.12325

@article{fa1000294bca4002a46113845cbae42a,

title = "Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion",

abstract = "To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies.",

author = "David, \{Sean P\} and Strong, \{David R\} and Leventhal, \{Adam M\} and Lancaster, \{Molly A\} and McGeary, \{John E\} and Munaf{\`o}, \{Marcus R\} and Bergen, \{Andrew W\} and Swan, \{Gary E\} and Benowitz, \{Neal L\} and Tyndale, \{Rachel F\} and Conti, \{David V\} and Brown, \{Richard A\} and Caryn Lerman and Raymond Niaura",

note = "{\textcopyright} 2013 Society for the Study of Addiction.",

year = "2013",

month = aug,

day = "14",

doi = "10.1111/add.12325",

language = "English",

journal = "Addiction",

issn = "1360-0443",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Influence of a dopamine pathway additive genetic efficacy score on smoking cessation

T2 - results from two randomized clinical trials of bupropion

AU - David, Sean P

AU - Strong, David R

AU - Leventhal, Adam M

AU - Lancaster, Molly A

AU - McGeary, John E

AU - Munafò, Marcus R

AU - Bergen, Andrew W

AU - Swan, Gary E

AU - Benowitz, Neal L

AU - Tyndale, Rachel F

AU - Conti, David V

AU - Brown, Richard A

AU - Lerman, Caryn

AU - Niaura, Raymond

PY - 2013/8/14

Y1 - 2013/8/14

N2 - To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies.

AB - To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies.

U2 - 10.1111/add.12325

DO - 10.1111/add.12325

M3 - Article (Academic Journal)

C2 - 23941313

SN - 1360-0443

JO - Addiction

JF - Addiction

ER -

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion

Abstract

Bibliographical note

Research Groups and Themes

Access to Document

Handle.net

Fingerprint

Cite this